Ischemic StrokeCASTORNCT02470624
Chinese Acute Ischemic Stroke Treatment Outcome Registry
An observational study of Ischemic Stroke, run by Peking University First Hospital at 1 site in China.
Trial summary
This is a multi-center registry study. The investigators will include 10,000 patients with confirmed acute ischemic stroke in China. The aim of the study is to survey current treatment situation in China and compare the effectiveness and safety between different intervention regimens. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ischemic Stroke
- What is being tested?
- treatment following current guideline
- How many people
- 10,000 participants
- Where
- 1 siteChina
- Study dates
- May 2015to Mar 2017
- How long will I take part?
- 18 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: acute ischemic stroke patients
Who may be able to join
- age ≥18 yesrs
- confirmed diagnosis of an ischemic stroke
- admission within 1 week after onset of stroke or within treatment time window for patients of thrombolysis treatment
- signed informed consent
Who cannot join
- with intracerebral hemorrhage
- with severe morbid (estimated survival duration less than 3 months)
- could not provide follow-up information
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Peking University First Hospital
Beijing, 100034
Yining Huang, MD, +86(10)83572857, ynhuang@sina.com
About this study
This is a multi-center registry study. The investigators will include 10,000 patients with confirmed acute ischemic stroke in China. The aim of the study is to survey current treatment situation in China and compare the effectiveness and safety between different intervention regimens.
Read the detailed description
Stroke is a common disease in China. Compared to western countries, there are many treatment regimens used in clinical practice in China. But their treatment effects are not well validated. The aim of the study is to survey current treatment situation in China and compare the effectiveness and safety between different intervention regimens.
- Conditions
- Ischemic Stroke
- Being tested
- treatment following current guideline
- Medical subject headings
- Ischemic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
treatment following current guidelineOther
| Study group | Role | What they receive |
|---|---|---|
| treatment following current guideline | Not described Receives: Other: treatment following current guideline |
What is being measured
The primary outcome is the main question the study is designed to answer.
death or severe disability
Measured: 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jun 2015 (estimated)
- Study startMay 2015
- Primary completionMar 2017 (estimated)
- Study completionMar 2017 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Ischemic StrokeStudies of the same condition, open and under way.
- More trials run by Peking University First HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 10,000 participants (estimated)
- Target duration
- 18 Months
Sponsor and investigators
- Lead sponsor
- Peking University First Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Techpool Bio-Pharma Co., Ltd.
- Responsible party
- Principal investigator, Yining Huang, Peking University First Hospital
- Investigators
- Yining Huang, MD, Principal investigator, Peking University First Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02470624
- Sponsor's protocol ID
- Neurology-stroke
- Acronym
- CASTOR
- Status last verified
- Oct 2015
- First submitted
- 10 Jun 2015
- Last updated
- 23 Oct 2015
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Li P, Zhao M, Huang Y, Sun W, Wang L, Jin X, Xie F, Li H. Interpreting patient-reported outcomes after ischemic stroke: defining minimal important difference in EQ-5D across recovery phases. Health Qual Life Outcomes. 2026 Mar 21;24(1):57. doi: 10.1186/s12955-026-02524-w.
PubMed 41864919Huang D, Lu Y, Sun W, Sun W, Sun Y, Huang Y, Song Y, Tai L, Li G, Chen H, Zhang G, Zhang L, Sun X, Qiu J, Wei Y, Jin H. Functional Outcomes of Human Urinary Kallindinogenases in Treatment of Acute Ischemic Stroke. Stroke. 2026 Jan;57(1):63-76. doi: 10.1161/STROKEAHA.124.050188. Epub 2025 Sep 29.
PubMed 41017461Lu Y, Sun W, Huang Y, Wang Z, Shen Z, Sun W, Liu R, Li F, Shu J, Peng Q, Jia J, Sun P, Song Y, Jin H; CASTOR Investigators. Comparison of Factors Affecting Quality of Life in Patients with Acute Ischemic Stroke Across Different Stroke Severities. Neurol Ther. 2025 Jun;14(3):1023-1038. doi: 10.1007/s40120-025-00743-9. Epub 2025 Apr 29.
PubMed 40301282Wang L, Guan X, Zhou J, Hu H, Liu W, Wei Q, Huang Y, Sun W, Jin X, Li H. Measuring the health outcomes of Chinese ischemic stroke patients based on the data from a longitudinal multi-center study. Qual Life Res. 2025 Jul;34(7):1967-1977. doi: 10.1007/s11136-025-03957-4. Epub 2025 Mar 27.
PubMed 40146503Lu Y, Sun P, Jin H, Wang Z, Shen Z, Sun W, Sun Y, Liu R, Li F, Shu J, Qiu Z, Lu Z, Sun W, Zhu S, Huang Y; CASTOR Investigators. Prolonged Hospital Length of Stay Does Not Improve Functional Outcome in Acute Ischemic Stroke. Neurol Ther. 2025 Apr;14(2):593-607. doi: 10.1007/s40120-025-00712-2. Epub 2025 Feb 18.
PubMed 39964661Li Y, Ou Q, Lu Y, Shen Z, Li J, Zhang Z, Tai L, Li G, Chen H, Zhang G, Zhang L, Sun X, Qiu J, Wei Y, Zhu S, Wang Z, Sun W, Huang Y. Geographic differences in pharmacotherapy patterns and outcomes of acute ischemic stroke in China. BMC Neurol. 2024 Feb 15;24(1):64. doi: 10.1186/s12883-024-03564-9.
PubMed 38360588Sun W, Ou Q, Zhang Z, Qu J, Huang Y. Chinese acute ischemic stroke treatment outcome registry (CASTOR): protocol for a prospective registry study on patterns of real-world treatment of acute ischemic stroke in China. BMC Complement Altern Med. 2017 Jul 6;17(1):357. doi: 10.1186/s12906-017-1863-4.
PubMed 28683732
Study at a glance
From the registry record, last updated by the sponsor on 23 Oct 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Chinese Acute Ischemic Stroke Treatment Outcome Registry
- ClinicalTrials.gov ID
- NCT02470624
- Acronym / sponsor ID
- CASTOR / Neurology-stroke
- Conditions
- Ischemic Stroke
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 10,000 participants (estimated)
- Lead sponsor
- Peking University First HospitalUniversity, hospital or other
- Collaborators
- Techpool Bio-Pharma Co., Ltd.
- Study start
- May 2015
- Primary completion
- Mar 2017 (estimated)
- Study completion
- Mar 2017 (estimated)
- First posted
- 12 Jun 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multi-center registry study. The investigators will include 10,000 patients with confirmed acute ischemic stroke in China. The aim of the study is to survey current treatment situation in China and compare the effectiveness and safety between different intervention regimens.
Detailed description
Stroke is a common disease in China. Compared to western countries, there are many treatment regimens used in clinical practice in China. But their treatment effects are not well validated. The aim of the study is to survey current treatment situation in China and compare the effectiveness and safety between different intervention regimens.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 18 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| treatment following current guideline | – | Other: treatment following current guideline |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- acute ischemic stroke patients
Key inclusion criteria (4 listed)
- age ≥18 yesrs
- confirmed diagnosis of an ischemic stroke
- admission within 1 week after onset of stroke or within treatment time window for patients of thrombolysis treatment
- signed informed consent
Key exclusion criteria (3 listed)
- with intracerebral hemorrhage
- with severe morbid (estimated survival duration less than 3 months)
- could not provide follow-up information
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| treatment following current guideline | Other | treatment following current guideline |
Primary outcome
death or severe disability
Time frame: 90 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Oct 2015.
- Derived from this study: PubMed 41864919Li P, Zhao M, Huang Y, Sun W, Wang L, Jin X, Xie F, Li H. Interpreting patient-reported outcomes after ischemic stroke: defining minimal important difference in EQ-5D across recovery phases. Health Qual Life Outcomes. 2026 Mar 21;24(1):57. doi: 10.1186/s12955-026-02524-w.
- Derived from this study: PubMed 41017461Huang D, Lu Y, Sun W, Sun W, Sun Y, Huang Y, Song Y, Tai L, Li G, Chen H, Zhang G, Zhang L, Sun X, Qiu J, Wei Y, Jin H. Functional Outcomes of Human Urinary Kallindinogenases in Treatment of Acute Ischemic Stroke. Stroke. 2026 Jan;57(1):63-76. doi: 10.1161/STROKEAHA.124.050188. Epub 2025 Sep 29.
- Derived from this study: PubMed 40301282Lu Y, Sun W, Huang Y, Wang Z, Shen Z, Sun W, Liu R, Li F, Shu J, Peng Q, Jia J, Sun P, Song Y, Jin H; CASTOR Investigators. Comparison of Factors Affecting Quality of Life in Patients with Acute Ischemic Stroke Across Different Stroke Severities. Neurol Ther. 2025 Jun;14(3):1023-1038. doi: 10.1007/s40120-025-00743-9. Epub 2025 Apr 29.
- Derived from this study: PubMed 40146503Wang L, Guan X, Zhou J, Hu H, Liu W, Wei Q, Huang Y, Sun W, Jin X, Li H. Measuring the health outcomes of Chinese ischemic stroke patients based on the data from a longitudinal multi-center study. Qual Life Res. 2025 Jul;34(7):1967-1977. doi: 10.1007/s11136-025-03957-4. Epub 2025 Mar 27.
- Derived from this study: PubMed 39964661Lu Y, Sun P, Jin H, Wang Z, Shen Z, Sun W, Sun Y, Liu R, Li F, Shu J, Qiu Z, Lu Z, Sun W, Zhu S, Huang Y; CASTOR Investigators. Prolonged Hospital Length of Stay Does Not Improve Functional Outcome in Acute Ischemic Stroke. Neurol Ther. 2025 Apr;14(2):593-607. doi: 10.1007/s40120-025-00712-2. Epub 2025 Feb 18.
- Derived from this study: PubMed 38360588Li Y, Ou Q, Lu Y, Shen Z, Li J, Zhang Z, Tai L, Li G, Chen H, Zhang G, Zhang L, Sun X, Qiu J, Wei Y, Zhu S, Wang Z, Sun W, Huang Y. Geographic differences in pharmacotherapy patterns and outcomes of acute ischemic stroke in China. BMC Neurol. 2024 Feb 15;24(1):64. doi: 10.1186/s12883-024-03564-9.
- Derived from this study: PubMed 28683732Sun W, Ou Q, Zhang Z, Qu J, Huang Y. Chinese acute ischemic stroke treatment outcome registry (CASTOR): protocol for a prospective registry study on patterns of real-world treatment of acute ischemic stroke in China. BMC Complement Altern Med. 2017 Jul 6;17(1):357. doi: 10.1186/s12906-017-1863-4.
Related trials for Ischemic Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Active, not recruiting
Improving Visual Field Deficits With Noninvasive Brain Stimulation
Visual Field Defect, Peripheral, Stroke
Recruiting
Biomarkers of Paired VNS
Stroke, Ischemic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yining Huang, MD principal investigator
Peking University First Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ischemic Stroke, run by Peking University First Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 23 Oct 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Yining Huang, MD (+86(10)83572857, ynhuang@sina.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
death or severe disability (time frame: 90 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02470624, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2015.